OneSource Specialty Pharma Ltd
OneSource Specialty Pharma Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
OneSource targets 25%-30% CAGR growth over the next 3-4 years, aiming for $400 million revenue. OneSource Specialty Pharma projects a revenue of $400 million in the next 3 to 4 years, growing at a CAGR of 25-30%.
From OneSource Specialty Pharma Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- OneSource targets 25%-30% CAGR growth over the next 3-4 years, aiming for $400 million revenue.
- GLP-1 cartridge capacity to increase 5x from 40 million to 220 million units by 2028.
- Expansion driven by new product approvals and increasing demand in emerging markets like Brazil, India, and China.
- Commercial sales (CSA) expected to grow from 20% to 80% of volumes by FY27.
- Anticipates a steady-state, predictable commercial business beyond FY27 with more than 40% EBITDA margins.
- Strong customer base with 20 GLP-1 customers and 60+ overall, supporting expanded capacity.
2 more points from OneSource Specialty Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what OneSource Specialty Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- OneSource Specialty Pharma plans to invest about $100 million in capex over the next 2 to 4 years.
- A significant part of this capex will be towards expanding drug-device combination (DDC) capacities.
- Additional investments will be made to add new capabilities in the injectable space.
- The company is proactively expanding capacities to meet growing customer demand, especially in the GLP-1 segment, increasing capacity from 40 million to 220 million units over 3 to 4 years.
- Some customers participate in the capex program, contributing to capacity reservation fees, sharing risk with OneSource.
2 more points from OneSource Specialty Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what OneSource Specialty Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- OneSource has customers providing reservation fees to block dedicated capacity.
- Customers have given forecasts ranging from 24 to 36 months, with 12 to 18 months being binding forecasts, equivalent to "take or pay" arrangements.
- The company proactively expands capacity to support customer demand.
- Current capacity of 40 million units is insufficient; plans are to increase capacity 5x to approximately 220 million units over 3 to 4 years.
- Strong demand and robust forecasts from 20 leading generic players, many of whom have significant market share.
2 more points from OneSource Specialty Pharma Ltd's call on order book
Pro opens every point from 15K+ earnings calls
OneSource Specialty Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹428 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What OneSource Speci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
OneSource Specialty Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were OneSource Specialty Pharma Ltd Q3 FY25 results?
OneSource targets 25%-30% CAGR growth over the next 3-4 years, aiming for $400 million revenue. OneSource Specialty Pharma projects a revenue of $400 million in the next 3 to 4 years, growing at a CAGR of 25-30%.
What is OneSource Specialty Pharma Ltd share price analysis?
OneSource Specialty Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,817 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Specialty Pharma Ltd planning capital expenditure?
OneSource Specialty Pharma plans to invest about $100 million in capex over the next 2 to 4 years.
Keep OneSource Specialty Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.